Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.
An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.
Miller
E
E
Public Health Laboratory Service, Communicable Disease Surveillance Centre, Colindale, London, UK.
Ashworth
L A
LA
Robinson
A
A
Waight
P A
PA
Irons
L I
LI
D000907:Antibodies, Bacterial / Q000032:analysis*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000145:classification / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D004890:Erythema / Q000209:etiology; D005069:Evaluation Studies as Topic; D005260:Female; D010861:Fimbriae, Bacterial / Q000276:immunology*; D006388:Hemagglutinins / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D037342:Pertussis Toxin; D011795:Surveys and Questionnaires; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000276:immunology*; D014917:Whooping Cough / Q000276:immunology* / Q000517:prevention & control
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin